Cargando…
Pyoderma gangrenosum treated with secukinumab: A case report
Pyoderma gangrenosum is a challenging disease to manage, due in part to the lack of approved treatment therapies. Recently, the emergence of biologic agents has expanded treatment options, with tumour necrosis factor alpha inhibitors being the best supported in the literature. In our report, we pres...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370553/ https://www.ncbi.nlm.nih.gov/pubmed/32733679 http://dx.doi.org/10.1177/2050313X20940430 |
| _version_ | 1783560998243794944 |
|---|---|
| author | McPhie, Meghan L Kirchhof, Mark G |
| author_facet | McPhie, Meghan L Kirchhof, Mark G |
| author_sort | McPhie, Meghan L |
| collection | PubMed |
| description | Pyoderma gangrenosum is a challenging disease to manage, due in part to the lack of approved treatment therapies. Recently, the emergence of biologic agents has expanded treatment options, with tumour necrosis factor alpha inhibitors being the best supported in the literature. In our report, we present a 50-year-old female with pyoderma gangrenosum who was successfully treated with the anti-interleukin-17 biologic agent, secukinumab, after failing other systemic therapies. |
| format | Online Article Text |
| id | pubmed-7370553 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73705532020-07-29 Pyoderma gangrenosum treated with secukinumab: A case report McPhie, Meghan L Kirchhof, Mark G SAGE Open Med Case Rep JCMS Case Report Pyoderma gangrenosum is a challenging disease to manage, due in part to the lack of approved treatment therapies. Recently, the emergence of biologic agents has expanded treatment options, with tumour necrosis factor alpha inhibitors being the best supported in the literature. In our report, we present a 50-year-old female with pyoderma gangrenosum who was successfully treated with the anti-interleukin-17 biologic agent, secukinumab, after failing other systemic therapies. SAGE Publications 2020-07-17 /pmc/articles/PMC7370553/ /pubmed/32733679 http://dx.doi.org/10.1177/2050313X20940430 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | JCMS Case Report McPhie, Meghan L Kirchhof, Mark G Pyoderma gangrenosum treated with secukinumab: A case report |
| title | Pyoderma gangrenosum treated with secukinumab: A case report |
| title_full | Pyoderma gangrenosum treated with secukinumab: A case report |
| title_fullStr | Pyoderma gangrenosum treated with secukinumab: A case report |
| title_full_unstemmed | Pyoderma gangrenosum treated with secukinumab: A case report |
| title_short | Pyoderma gangrenosum treated with secukinumab: A case report |
| title_sort | pyoderma gangrenosum treated with secukinumab: a case report |
| topic | JCMS Case Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370553/ https://www.ncbi.nlm.nih.gov/pubmed/32733679 http://dx.doi.org/10.1177/2050313X20940430 |
| work_keys_str_mv | AT mcphiemeghanl pyodermagangrenosumtreatedwithsecukinumabacasereport AT kirchhofmarkg pyodermagangrenosumtreatedwithsecukinumabacasereport |